GLP-1 (5mg)

Recent research & studies

• Incretin Therapies in Obesity-related HFpEF — ClinicalTrials.gov • Recruiting • Phase4 • August 24, 2026

  The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this…

• Semaglutide Therapy for Alcohol Reduction (STAR) — ClinicalTrials.gov • Active Not Recruiting • Phase2 • August 24, 2026

  Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective: To test…

• Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study) — ClinicalTrials.gov • Recruiting • Phase2 • August 24, 2026

  Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how…

• Avexitide for Treatment of Post-Bariatric Hypoglycemia — ClinicalTrials.gov • Active Not Recruiting • Phase3 • August 24, 2026

  AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by…

• Efficacy of a Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use: A Clinical, Subjective, and Trichogram Evaluation — ClinicalTrials.gov • Not Yet Recruiting • Na • August 24, 2026

  A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through…

• State-Level Variation in GLP-1 Receptor Agonist Use Among Medicaid Beneficiaries Without Diabetes by State Obesity Coverage Policy. — PubMed • Dun C et al. • Diabetes Care • 2026 Aug 24

These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.